Colin Biggin

Dr Biggin has 15 years of radiopharmaceutical development and commercialization experience. He previously served with Algeta ASA during the development and commercialization of its product Xofigo (radium-223 dichloride) for metastatic prostate cancer, which was approved by the US FDA in 2013. Prior to joining the Company, he also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.

Holding

Company	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
CU6	08/04/26	4,926,458	N/A	2,540,200	N/A

Transactions

Company	Date	Type	Amount	Price	Value	Notes
CU6	25/11/25	Issued	487,439	$1.616	$787,875	Issue of options
CU6	01/07/25	Exercise	1,000,000	$0.938	$937,500	Exercise of options
CU6	01/07/25	Buy	592,373	$1.583	$937,500	Exercise of options
CU6	20/11/24	Issued	285,918	$2.756	$787,875	Issue of options
CU6	01/10/24	Buy	1,084,321	$0.913	$990,000	Exercise of options

Any feedback about this profile? Contact Us

Build your watchlist

Already have account? Log in